» Articles » PMID: 33301029

MYC-induced Human Acute Myeloid Leukemia Requires a Continuing IL-3/GM-CSF Costimulus

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2020 Dec 10
PMID 33301029
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Hematopoietic clones with leukemogenic mutations arise in healthy people as they age, but progression to acute myeloid leukemia (AML) is rare. Recent evidence suggests that the microenvironment may play an important role in modulating human AML population dynamics. To investigate this concept further, we examined the combined and separate effects of an oncogene (c-MYC) and exposure to interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem cell factor (SCF) on the experimental genesis of a human AML in xenografted immunodeficient mice. Initial experiments showed that normal human CD34+ blood cells transduced with a lentiviral MYC vector and then transplanted into immunodeficient mice produced a hierarchically organized, rapidly fatal, and serially transplantable blast population, phenotypically and transcriptionally similar to human AML cells, but only in mice producing IL-3, GM-CSF, and SCF transgenically or in regular mice in which the cells were exposed to IL-3 or GM-CSF delivered using a cotransduction strategy. In their absence, the MYC+ human cells produced a normal repertoire of lymphoid and myeloid progeny in transplanted mice for many months, but, on transfer to secondary mice producing the human cytokines, the MYC+ cells rapidly generated AML. Indistinguishable diseases were also obtained efficiently from both primitive (CD34+CD38-) and late granulocyte-macrophage progenitor (GMP) cells. These findings underscore the critical role that these cytokines can play in activating a malignant state in normally differentiating human hematopoietic cells in which MYC expression has been deregulated. They also introduce a robust experimental model of human leukemogenesis to further elucidate key mechanisms involved and test strategies to suppress them.

Citing Articles

TIFAB modulates metabolic pathways in KMT2A::MLLT3-induced AML through HNF4A.

Wang Y, Xiu Y, Dong Q, Zhao J, Neumbo K, Miyagi M Blood Adv. 2024; 9(4):844-855.

PMID: 39626355 PMC: 11872587. DOI: 10.1182/bloodadvances.2024013446.


Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.

Safa-Tahar-Henni S, Paez Martinez K, Gress V, Esparza N, Roques E, Bonnet-Magnaval F Leukemia. 2024; 39(1):29-41.

PMID: 39472547 PMC: 11717705. DOI: 10.1038/s41375-024-02400-w.


Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia.

Alonso-Perez V, Galant K, Boudia F, Robert E, Aid Z, Renou L Mol Cancer. 2024; 23(1):204.

PMID: 39304903 PMC: 11414260. DOI: 10.1186/s12943-024-02110-y.


Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis.

Vincelette N, Yu X, Kuykendall A, Moon J, Su S, Cheng C Blood Cancer Discov. 2024; 5(4):276-297.

PMID: 38713018 PMC: 11215389. DOI: 10.1158/2643-3230.BCD-23-0210.


translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression.

Xu W, Tian F, Tai X, Song G, Liu Y, Fan L Haematologica. 2024; 109(8):2445-2458.

PMID: 38356460 PMC: 11290521. DOI: 10.3324/haematol.2023.284121.